Another important result of the present study is that, in our patients, the doubling of the dose of LVF supplementation was not associated with changes in JIA disease activity measures such as the composite tool for scoring, JADAS, and the acute phase reactants, ESR and CRP. This evidence concerns the gene CRP and juvenile idiopathic arthritis.